Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for VTE Prevention in Ovarian Cancer
NCT04352439Phase 4Completed
- Sponsor
- Duke University
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aspirin in venous thromboembolism (VTE), sponsored by Duke University. Primary endpoints: Number of Participants Experiencing a Venous Thromboembolism at 6 months, Number of Participants With at Least One Adverse Event at 6 months and 1 more. Started Aug 2020; status: completed.
02
Drugs
aspirin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04352439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352439.